Works by Maemondo, Makoto

Results: 60
    1

    A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non--Small Cell Lung Cancer Study: (NEJ048A/NEXUS).

    Published in:
    Clinical Lung Cancer, 2023, v. 24, n. 4, p. 371, doi. 10.1016/j.cllc.2023.01.008
    By:
    • Akihiko Miyanaga;
    • Hajime Asahina;
    • Satoshi Watanabe;
    • Takehito Shukuya;
    • Yukari Tsubata;
    • Yukio Hosomi;
    • Shunichi Sugawara;
    • Makoto Maemondo;
    • Tetsuya Okano;
    • Satoshi Morita;
    • Kotone Matsuyama;
    • Kunihiko Kobayashi;
    • Masahiro Seike
    Publication type:
    Article
    2
    3

    First-line nivolumab plus ipilimumab with or without chemotherapy for Japanese patients with non-small cell lung cancer: LIGHT-NING study.

    Published in:
    Japanese Journal of Clinical Oncology, 2024, v. 54, n. 4, p. 452, doi. 10.1093/jjco/hyad195
    By:
    • Imai, Hisao;
    • Kijima, Takashi;
    • Azuma, Koichi;
    • Kishi, Kazuma;
    • Saito, Haruhiro;
    • Yamaguchi, Teppei;
    • Tanizaki, Junko;
    • Yoneshima, Yasuto;
    • Fujita, Kohei;
    • Watanabe, Satoshi;
    • Kitazono, Satoru;
    • Fukuhara, Tatsuro;
    • Hataji, Osamu;
    • Toi, Yukihiro;
    • Mizutani, Hideaki;
    • Hamakawa, Yusuke;
    • Maemondo, Makoto;
    • Ohsugi, Tomoyuki;
    • Suzuki, Keisuke;
    • Horinouchi, Hidehito
    Publication type:
    Article
    4

    Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies.

    Published in:
    Japanese Journal of Clinical Oncology, 2021, v. 51, n. 1, p. 106, doi. 10.1093/jjco/hyaa157
    By:
    • Saka, Hideo;
    • Nishio, Makoto;
    • Hida, Toyoaki;
    • Nakagawa, Kazuhiko;
    • Sakai, Hiroshi;
    • Nogami, Naoyuki;
    • Atagi, Shinji;
    • Takahashi, Toshiaki;
    • Horinouchi, Hidehito;
    • Takenoyama, Mitsuhiro;
    • Katakami, Nobuyuki;
    • Tanaka, Hiroshi;
    • Takeda, Koji;
    • Satouchi, Miyako;
    • Isobe, Hiroshi;
    • Maemondo, Makoto;
    • Goto, Koichi;
    • Hirashima, Tomonori;
    • Minato, Koichi;
    • Yada, Nobumichi
    Publication type:
    Article
    5

    Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer--data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).

    Published in:
    Japanese Journal of Clinical Oncology, 2015, v. 45, n. 7, p. 670, doi. 10.1093/jjco/hyv054
    By:
    • Eisaku Miyauchi;
    • Akira Inoue;
    • Kunihiko Kobayashi;
    • Makoto Maemondo;
    • Shunichi Sugawara;
    • Satoshi Oizumi;
    • Hiroshi Isobe;
    • Akihiko Gemma;
    • Yasuo Saijo;
    • Hirohisa Yoshizawa;
    • Koichi Hagiwara;
    • Toshihiro Nukiwa
    Publication type:
    Article
    6
    7
    8
    9
    10
    11

    Usefulness of linezolid in the treatment of hospital-acquired pneumonia caused by MRSA: a prospective observational study.

    Published in:
    Journal of Infection & Chemotherapy (Springer Science & Business Media B.V.), 2012, v. 18, n. 2, p. 160, doi. 10.1007/s10156-011-0309-z
    By:
    • Watanabe, Akira;
    • Goto, Hajime;
    • Soma, Kazui;
    • Kikuchi, Toshiaki;
    • Gomi, Kazunori;
    • Miki, Hiroshi;
    • Maemondo, Makoto;
    • Ikeda, Hideki;
    • Kuroki, Jun;
    • Wada, Hiroo;
    • Yokoyama, Takuma;
    • Izumi, Shinyu;
    • Mitsutake, Kotaro;
    • Ueda, Yasuharu
    Publication type:
    Article
    12

    Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial.

    Published in:
    2012
    By:
    • Oizumi, Satoshi;
    • Kobayashi, Kunihiko;
    • Inoue, Akira;
    • Maemondo, Makoto;
    • Sugawara, Shunichi;
    • Yoshizawa, Hirohisa;
    • Isobe, Hiroshi;
    • Harada, Masao;
    • Kinoshita, Ichiro;
    • Okinaga, Shoji;
    • Kato, Terufumi;
    • Harada, Toshiyuki;
    • Gemma, Akihiko;
    • Saijo, Yasuo;
    • Yokomizo, Yuki;
    • Morita, Satoshi;
    • Hagiwara, Koichi;
    • Nukiwa, Toshihiro
    Publication type:
    Journal Article
    13

    Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial.

    Published in:
    Oncologist, 2012, v. 17, n. 6, p. 863, doi. 10.1634/theoncologist.2011-0426
    By:
    • OIZUMI, SATOSHI;
    • KOBAYASHI, KUNIHIKO;
    • INOUE, AKIRA;
    • MAEMONDO, MAKOTO;
    • SUGAWARA, SHUNICHI;
    • YOSHIZAWA, HIROHISA;
    • ISOBE, HIROSHI;
    • HARADA, MASAO;
    • KINOSHITA, ICHIRO;
    • OKINAGA, SHOJI;
    • KATO, TERUFUMI;
    • HARADA, TOSHIYUKI;
    • GEMMA, AKIHIKO;
    • SAIJO, YASUO;
    • YOKOMIZO, YUKI;
    • MORITA, SATOSHI;
    • HAGIWARA, KOICHI;
    • NUKIWA, TOSHIHIRO
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20

    First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 4, p. 695, doi. 10.1007/s10147-022-02120-0
    By:
    • John, Thomas;
    • Sakai, Hiroshi;
    • Ikeda, Satoshi;
    • Cheng, Ying;
    • Kasahara, Kazuo;
    • Sato, Yuki;
    • Nakahara, Yoshiro;
    • Takeda, Masayuki;
    • Kaneda, Hiroyasu;
    • Zhang, Helong;
    • Maemondo, Makoto;
    • Minato, Koichi;
    • Hisada, Takeshi;
    • Misumi, Yuki;
    • Satouchi, Miyako;
    • Hotta, Katsuyuki;
    • Li, Ang;
    • Oukessou, Abderrahim;
    • Lu, Shun
    Publication type:
    Article
    21

    Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).

    Published in:
    2022
    By:
    • Tsubata, Yukari;
    • Watanabe, Kana;
    • Saito, Ryota;
    • Nakamura, Atsushi;
    • Yoshioka, Hiroshige;
    • Morita, Mami;
    • Honda, Ryoichi;
    • Kanaji, Nobuhiro;
    • Oizumi, Satoshi;
    • Jingu, Daisuke;
    • Nakagawa, Taku;
    • Nakazawa, Kensuke;
    • Mouri, Atsuto;
    • Takeuchi, Susumu;
    • Furuya, Naoki;
    • Akazawa, Yuki;
    • Miura, Kiyotaka;
    • Ichihara, Eiki;
    • Maemondo, Makoto;
    • Morita, Satoshi
    Publication type:
    Correction Notice
    22

    Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 1, p. 112, doi. 10.1007/s10147-021-02043-2
    By:
    • Tsubata, Yukari;
    • Watanabe, Kana;
    • Saito, Ryota;
    • Nakamura, Atsushi;
    • Yoshioka, Hiroshige;
    • Morita, Mami;
    • Honda, Ryoichi;
    • Kanaji, Nobuhiro;
    • Ohizumi, Satoshi;
    • Jingu, Daisuke;
    • Nakagawa, Taku;
    • Nakazawa, Kensuke;
    • Mouri, Atsuto;
    • Takeuchi, Susumu;
    • Furuya, Naoki;
    • Akazawa, Yuki;
    • Miura, Kiyotaka;
    • Ichihara, Eiki;
    • Maemondo, Makoto;
    • Morita, Satoshi
    Publication type:
    Article
    23

    Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

    Published in:
    International Journal of Clinical Oncology, 2019, v. 24, n. 5, p. 485, doi. 10.1007/s10147-019-01396-z
    By:
    • Sugawara, Shunichi;
    • Nakagawa, Kazuhiko;
    • Yamamoto, Nobuyuki;
    • Nokihara, Hiroshi;
    • Ohe, Yuichiro;
    • Nishio, Makoto;
    • Takahashi, Toshiaki;
    • Goto, Koichi;
    • Maemondo, Makoto;
    • Ichinose, Yukito;
    • Seto, Takashi;
    • Sakai, Hiroshi;
    • Gemma, Akihiko;
    • Imamura, Fumio;
    • Shingyoji, Masato;
    • Saka, Hideo;
    • Inoue, Akira;
    • Takeda, Koji;
    • Okamoto, Isamu;
    • Kiura, Katsuyuki
    Publication type:
    Article
    24

    Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer.

    Published in:
    International Journal of Clinical Oncology, 2017, v. 22, n. 1, p. 70, doi. 10.1007/s10147-016-1039-0
    By:
    • Yamamoto, Noboru;
    • Goto, Koichi;
    • Nishio, Makoto;
    • Chikamori, Kenichi;
    • Hida, Toyoaki;
    • Maemondo, Makoto;
    • Katakami, Nobuyuki;
    • Kozuki, Toshiyuki;
    • Yoshioka, Hiroshige;
    • Seto, Takashi;
    • Tajima, Kosei;
    • Tamura, Tomohide
    Publication type:
    Article
    25
    26

    Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.

    Published in:
    International Journal of Clinical Oncology, 2016, v. 21, n. 5, p. 996, doi. 10.1007/s10147-016-0971-3
    By:
    • Tamura, Kazuo;
    • Kawai, Yasukazu;
    • Kiguchi, Toru;
    • Okamoto, Masataka;
    • Kaneko, Masahiko;
    • Maemondo, Makoto;
    • Gemba, Kenichi;
    • Fujimaki, Katsumichi;
    • Kirito, Keita;
    • Goto, Tetsuya;
    • Fujisaki, Tomoaki;
    • Takeda, Kenji;
    • Nakajima, Akihiro;
    • Ueda, Takanori
    Publication type:
    Article
    27
    28
    29
    30
    31
    32

    Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

    Published in:
    Thoracic Cancer, 2021, v. 12, n. 14, p. 2113, doi. 10.1111/1759-7714.14048
    By:
    • Hisashi Tanaka;
    • Yukihiro Hasegawa;
    • Yuka Fujita;
    • Atsushi Nakamura;
    • Eiki Kikuchi;
    • Yasutaka Kawai;
    • Toshiyuki Harada;
    • Naomi Watanabe;
    • Hiroshi Yokouchi;
    • Kazuhiro Usui;
    • Ryota Saito;
    • Hiroshi Watanabe;
    • Tomomi Masuda;
    • Tatsuro Fukuhara;
    • Keita Kudo;
    • Ryoichi Honda;
    • Satoshi Oizimi;
    • Makoto Maemondo;
    • Akira Inoue;
    • Naoto Morikawa
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39

    Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.

    Published in:
    2020
    By:
    • Papadimitrakopoulou, Vassiliki A.;
    • Han, Ji‐Youn;
    • Ahn, Myung‐Ju;
    • Ramalingam, Suresh S.;
    • Delmonte, Angelo;
    • Hsia, Te‐Chun;
    • Laskin, Janessa;
    • Kim, Sang‐We;
    • He, Yong;
    • Tsai, Chun‐Ming;
    • Hida, Toyoaki;
    • Maemondo, Makoto;
    • Kato, Terufumi;
    • Jenkins, Suzanne;
    • Patel, Sabina;
    • Huang, Xiangning;
    • Laus, Gianluca;
    • Markovets, Aleksandra;
    • Thress, Kenneth S.;
    • Wu, Yi‐Long
    Publication type:
    journal article
    40

    Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9.

    Published in:
    Cancer Science, 2018, v. 109, n. 9, p. 2863, doi. 10.1111/cas.13721
    By:
    • Hida, Toyoaki;
    • Seto, Takashi;
    • Horinouchi, Hidehito;
    • Maemondo, Makoto;
    • Takeda, Masayuki;
    • Hotta, Katsuyuki;
    • Hirai, Fumihiko;
    • Kim, Young Hak;
    • Matsumoto, Shingo;
    • Ito, Masayuki;
    • Ayukawa, Koichi;
    • Tokushige, Kota;
    • Yonemura, Masataka;
    • Mitsudomi, Testuya;
    • Nishio, Makoto
    Publication type:
    Article
    41

    Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.

    Published in:
    Cancer Science, 2017, v. 108, n. 5, p. 1000, doi. 10.1111/cas.13225
    By:
    • Hida, Toyoaki;
    • Nishio, Makoto;
    • Nogami, Naoyuki;
    • Ohe, Yuichiro;
    • Nokihara, Hiroshi;
    • Sakai, Hiroshi;
    • Satouchi, Miyako;
    • Nakagawa, Kazuhiko;
    • Takenoyama, Mitsuhiro;
    • Isobe, Hiroshi;
    • Fujita, Shiro;
    • Tanaka, Hiroshi;
    • Minato, Koichi;
    • Takahashi, Toshiaki;
    • Maemondo, Makoto;
    • Takeda, Koji;
    • Saka, Hideo;
    • Goto, Koichi;
    • Atagi, Shinji;
    • Hirashima, Tomonori
    Publication type:
    Article
    42
    43
    44
    45

    Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 11, p. 5183, doi. 10.1002/cam4.2411
    By:
    • Horinouchi, Hidehito;
    • Nishio, Makoto;
    • Hida, Toyoaki;
    • Nakagawa, Kazuhiko;
    • Sakai, Hiroshi;
    • Nogami, Naoyuki;
    • Atagi, Shinji;
    • Takahashi, Toshiaki;
    • Saka, Hideo;
    • Takenoyama, Mitsuhiro;
    • Katakami, Nobuyuki;
    • Tanaka, Hiroshi;
    • Takeda, Koji;
    • Satouchi, Miyako;
    • Isobe, Hiroshi;
    • Maemondo, Makoto;
    • Goto, Koichi;
    • Hirashima, Tomonori;
    • Minato, Koichi;
    • Sumiyoshi, Naoki
    Publication type:
    Article
    46
    47
    48
    49

    Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues.

    Published in:
    International Journal of Biological Markers, 2015, v. 30, n. 2, p. e234, doi. 10.5301/jbm.5000131
    By:
    • Sodai Narumi;
    • Yasuhiro Miki;
    • Shuko Hata;
    • Masahito Ebina;
    • Mikiyoshi Saito;
    • Kazushige Mori;
    • Makoto Kobayashi;
    • Takashi Suzuki;
    • Erina Iwabuchi;
    • Ikuro Sato;
    • Makoto Maemondo;
    • Chiaki Endo;
    • Akira Inoue;
    • Takashi Kondo;
    • Hisafumi Yamada-Okabe;
    • Masakazu Ichinose;
    • Hironobu Sasano
    Publication type:
    Article
    50